Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Vitrified human ovaries have fewer primordial follicles and produce less antimüllerian hormone than slow-frozen ovaries Ozgur Oktem, M.D., Ebru Alper,

Direct vitamin D3 actions on rhesus macaque follicles in three-dimensional culture: assessment of follicle survival, growth, steroid, and antimüllerian.

Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann,

Nicole Banks, M. D. , George Patounakis, M. D. , Ph. D

Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle Michael W.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Antimüllerian hormone levels and numbers and sizes of antral follicles in regularly menstruating women of reproductive age referenced to true ovulation.

Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol Qi Yao, Yuanjiao Liang, Yong.

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority.

Patient-tailored ovarian stimulation for in vitro fertilization

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages Maribel.

Combining cycle day 7 follicle count with the basal antral follicle count improves the prediction of ovarian response Fatih Durmusoglu, M.D., Koray Elter,

Antimüllerian hormone levels and antral follicle count as prognostic indicators in a personalized prediction model of live birth Scott M. Nelson, M.R.C.O.G.,

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone–stratified, dose–response trial in women undergoing.

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained.

Antral follicle count as a predictor of ovarian responsiveness in women with endometriomas or with a history of surgery for endometriomas Laura Benaglia,

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Biomarkers of ovarian response: current and future applications

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting Karl R Hansen, M.D., Ph.D., Jamie L Morris,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S

Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool Richard.

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron.

Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement Fertility and Sterility Volume 102,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a.

Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Stephanie L. F. Gustin, M. D. , Gourab Mukherjee, Valerie L. Baker, M

Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.

Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Progesterone-to-follicle index is better correlated with in vitro fertilization cycle outcome than blood progesterone level Yoel Shufaro, M.D., Ph.D.,

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

One-year follow-up of serum antimüllerian hormone levels in patients with cystectomy: are different sequential changes due to different mechanisms causing.

A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child Xin Chen, M.D., M.Sc., Shi-ling Chen,

Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients Scott M. Nelson, Ph.D., Martina C. Messow,

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Performance of basal follicle-stimulating hormone and patient's age in the prediction of poor ovarian response and IVF outcome of women who developed.

Brooks A. Keel, Ph.D., H.C.L.D.(A.B.B.) Fertility and Sterility

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.

Presentation transcript:

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials Scott M. Nelson, M.R.C.O.G., Ph.D., Bjarke M. Klein, Ph.D., Joan-Carles Arce, M.D., Ph.D. Fertility and Sterility Volume 103, Issue 4, Pages 923-930.e1 (April 2015) DOI: 10.1016/j.fertnstert.2014.12.114 Copyright © 2015 The Authors Terms and Conditions

Figure 1 Correlations between AMH and AFC, respectively, and number of oocytes retrieved in patients participating in a long GnRH agonist trial (A) and a GnRH antagonist trial (B) at individual IVF clinics. The dotted lines show the overall mean correlation coefficients of AMH and AFC for the study cohorts. Antimüllerian hormone was a stronger predictor of oocyte yield (i.e., a difference in correlation coefficient of >0.10) in study center nos. 1, 3, 4, 5, 6, 9, 11, 12, 14, 16, 17, 18, and 19 in the long GnRH agonist trial, and in study center nos. 1, 2, 3, 4, 9, 11, 12, 13, 14, 15, 17, and 18 in the GnRH antagonist trial. Only study center no. 15 in the long GnRH agonist trial exhibited a stronger association with AFC. Fertility and Sterility 2015 103, 923-930.e1DOI: (10.1016/j.fertnstert.2014.12.114) Copyright © 2015 The Authors Terms and Conditions

Figure 2 Panels illustrating the capability of AMH and AFC to predict the number of oocytes retrieved for the long GnRH agonist trial (left) and the GnRH antagonist trial (right). The upper panels (A, B) show the partial residuals from the model including study cohort, AFC, and Study Center plotted against AMH. The lower panels (C, D) show the partial residuals from the model including study cohort, AMH, and Study Center plotted against AFC. Fertility and Sterility 2015 103, 923-930.e1DOI: (10.1016/j.fertnstert.2014.12.114) Copyright © 2015 The Authors Terms and Conditions

Supplemental Figure 1 Diagram showing the data selection procedure. *Patients who underwent oocyte retrieval and had assessments of both AMH and AFC at stimulation day 1. Fertility and Sterility 2015 103, 923-930.e1DOI: (10.1016/j.fertnstert.2014.12.114) Copyright © 2015 The Authors Terms and Conditions